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Background: Mutations in the MYOC gene have been shown to explain 5% of unrelated primary 
open angle glaucoma (POAG) in different populations. In particular, the T377M MYOC muta-
tion has arisen at least three separate times in history, in Great Britain, India, and Greece. The 
purpose of this study is to investigate the distribution of the mutation among different population 
groups in the northwestern region of Greece.
Materials and methods: We explored the distribution of the “Greek” T377M founder muta-
tion in the Epirus region in Northwestern Greece, which could be its origin. Genotyping was 
performed in POAG cases and controls by PCR amplification of the MYOC gene, followed by 
digestion with restriction enzyme. Statistical analyses were performed by an exact test, the 
Kaplan–Meier method and the t-test.
Results: In the isolated Chrysovitsa village in the Pindus Mountains, a large POAG family 
demonstrated the T377M mutation in 20 of 66 family members while no controls from the Epirus 
region (n = 124) carried this mutation (P  0.001). Among other POAG cases from Epirus, 
2 out of 14 familial cases and 1 out of 80 sporadic cases showed the mutation (P = 0.057). The 
probability of POAG diagnosis with advancing age among mutation carriers was 23% at age 40, 
and reached 100% at age 75. POAG patients with the T377M mutation were diagnosed at a 
mean age of 51 years (SD ± 13.9), which is younger than the sporadic or familial POAG cases: 
63.1 (SD ± 11) and 66.8 (SD ± 9.8) years, respectively.
Conclusions: The T377M mutation was found in high proportion in members of the Chryso-
vitsa family (30.3%), in lower proportion in familial POAG cases (14.2%) and seems rare 
in sporadic POAG cases (1.2%), while no controls (0%) from the Epirus region carried the 
mutation. Historical and geographical data may explain the distribution of this mutation within 
Greece and worldwide.
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Introduction
Glaucoma is a heterogeneous group of disorders resulting from optic nerve damage 
and is the second leading cause of irreversible blindness worldwide. Primary open 
angle glaucoma (POAG) is the most common form, with reported prevalence rates 
ranging from 1.1%1 to 3.8%.2 The definition of glaucoma has changed many times as 
the etiology and pathogenetic pathways are still largely unknown. A high intraocular 
pressure (IOP) is no longer considered part of the definition of POAG, but represents 
a risk factor for the development of POAG.3 Other risk factors are old age, race, and 
positive family history.4 At the genetic level, a distinction between juvenile onset (age at 
diagnosis 10–35 years) and adult onset (age at diagnosis above 35 years) has been made. Clinical Ophthalmology 2010:4 172
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Many juvenile onset cases have autosomal dominant inheritance 
whilst adult onset cases are typically multifactorial.
The first locus related to juvenile onset glaucoma was 
mapped to chromosome 1q21-q31 (GLC1A).5 A common 
POAG locus for both juvenile and adult onset POAG was sug-
gested from the study of a large Canadian family with linkage 
to the GLC1A locus and different ages of onset.6 Other pedi-
grees with adult onset POAG excluded linkage to the GLC1A 
locus.7,8 The gene encoding myocilin (MYOC), located in 
1q23-q24, consists of 3 exons, and shows high expression 
in the trabecular meshwork and ciliary body.9 Mutations in 
the MYOC gene were finally identified as responsible for 
glaucoma at the GLC1A locus.9 Large studies have demon-
strated that point mutations in MYOC account for 4.6% of 
unrelated POAG patients.10 Patients with POAG due to MYOC 
mutations show marked phenotypic variation with age at 
diagnosis ranging from 8 to 77 years and highest recorded 
IOP ranging from 12 to 77 mm Hg.10 To date approximately 
60 disease-causing MYOC mutations have been reported, and 
a genotype-phenotype correlation exists.11
Evidence for founder effects of several MYOC mutations 
has been reported in different populations.12–16 The T377M 
mutation was first described in 1998 and has since been 
identified in populations from five different continents.17–25 
An investigation of founder effects for this mutation has 
demonstrated that it has arisen at least three separate times, 
namely in Great Britain, India, and Greece.16 The purpose of 
the present study is to determine the prevalence of the Greek 
T377M founder mutation in familial and sporadic cases of 
POAG and unaffected controls in Epirus, the Northwestern 
region of Greece, and to discuss geographical and historical 
data to assist explaining the propagation of this mutation in 
Greece and worldwide. We also describe the clinical charac-
teristics of the T377M mutation carriers in our material.
Materials and methods
Sporadic and familial POAG patients from Epirus, North-
west Greece, as well as unaffected controls from the same 
region were recruited. POAG patients were recruited from 
the Glaucoma Unit of the Department of Ophthalmology, 
University of Ioannina School of Medicine, or from the 
Department of Ophthalmology, General Hospital of Ioannina 
“G. Chatzikosta”. All 200 POAG patients seen in follow-up 
between April 2005 and January 2006 at the two hospitals 
were asked to participate in the study and 94 of them gave 
their consent and had blood drawn for genetic testing. The 
106 non responders for blood testing, had POAG of the same 
severity (max IOP, c/d ratio, visual fields) and their ethnicity, 
their age at diagnosis, age at examination and sex matched 
the group that gave their consent. These two hospitals cover the 
entire Epirus region. Of the 94 cases, 80 were sporadic and 
14 had a positive family history of POAG, which was con-
firmed by clinical examination of family members.
Members of a large family with POAG segregating as 
a monogenic trait (GLC1C) were recruited from a previous 
study.26 The T377M MYOC mutation was found to segregate 
in a large proportion of the members of this family.24 The 
family originated from the Chrysovitsa village of the Pindus 
Mountains, Epirus. A total of 66 out of 73 family members 
were available for the present study. Furthermore, we included 
4 sporadic POAG cases and 4 individuals without POAG 
(controls) from the Chrysovitsa village, who were not related 
to the pedigree described above, and which are included in 
the sporadic POAG and control groups, respectively.
Unaffected Epirus residents were selected as controls 
from patients admitted to cataract surgery in the Depart-
ment of Ophthalmology, General Hospital of Ioannina 
“G Chatzikosta”, between April 2005 and January 2006. 
A total number of 124 controls were recruited, of which 
24 individuals had pseudoexfoliative material in the ante-
rior chamber of one or both eyes (without glaucoma).
The protocol was approved by the Ethics Committees of 
the University of Ioannina School of Medicine, the General 
Hospital of Ioannina “G Chatzikosta”, and the Institute of Child 
Health, Athens. The clinical examination protocol included 
an interview to determine the presence of family history of 
POAG, full medical history, and history of ophthalmologic dis-
orders. Applanation tonometry was performed with a recently 
calibrated Goldmann applanation tonometer (Haag Streit AG, 
Bern, Switzerland). The anterior segment was examined by slit 
lamp biomicroscopy including gonioscopy. Optic disc appear-
ance was evaluated and the cup/disc ratio was measured. Quali-
tative signs of POAG, such as bared circumpapillary vessels, 
disc hemorrhages, focal neuroretinal rim thinning or a notch 
extending to the margin, as well as retinal fiber layer defects, 
were assessed with a stereoscopic fundus lens (Volk Optical 
Inc., Mentor, Ohio). Automated perimetry by Humphrey 24-2 
(Humphrey Inc., San Leandro, CA, USA) was performed to 
determine visual field defects in the POAG patients. Staging 
of the perimetry results (Early Glaucomatous Loss, Moderate 
Glaucomatous Loss and Advanced Glaucomatous Loss) was 
done according to Hodapp classification, as suggested by the 
European Glaucoma Society.27,28 Ocular hypertension (OHT) 
was defined as IOP  21 mm Hg, with all other ocular find-
ings within normal limits. The criteria for the diagnosis of 
POAG were according to the guidelines of the European Clinical Ophthalmology 2010:4 173
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Glaucoma Society.27 Patients with pseudoexfoliation glaucoma 
were excluded from the study. The clinical examination pro-
tocol, except for the automated perimetry, was also performed 
in the controls.
Venous blood was drawn from patients and controls follow-
ing informed consent, and DNA was obtained by a salt extrac-
tion method.29 Genotyping of the T377M MYOC mutation 
was performed by PCR amplification of genomic DNA using 
a modified protocol of Melki et al.22 The primers used were 
MYOC-F (5′– GATTATGGATTAAGTGGTGCTTCG – 3′) and 
MYOC-R (5′ – TGAGCATCTCCTTCTGCCATTGCC – 3′). 
A fragment of 874 bp was amplified according to the follow-
ing protocol: 94°C for 5 minutes, followed by 35 cycles of 
94°C for 30 seconds, 58°C for 30 seconds, 72°C for 1 minute, 
and final extension of 72°C for 7 minutes. The unpurified 
PCR product was subsequently digested with Hsp92 II 
enzyme (Promega Corporation, Madison, Wisconsin) at 37°C 
for 24 hours and digests were run on a 9% polyacrylamide 
gel in TBE buffer at 90 V for 3 hours. HSP92II recognizes 
a CATG restriction site, and therefore, the wild-type DNA 
yielded 3 fragments of 740, 80, and 54 bp, while the T377M 
mutation creates a restriction site with fragments of 443, 297, 
80, and 54 bp (Figure 1).
Mutation carrier rates between groups were compared 
with an exact test. Time-to-POAG diagnosis analysis used the 
Kaplan–Meier method. Comparison of continuous measures 
used the t-test. P values were two-tailed.
Results
Prevalence of T377M in various groups
The results of T377M MYOC genotyping in POAG patients 
and unaffected controls are summarized in Table 1. In the 
Chrysovitsa family segregating POAG as an autosomal 
dominant trait, 20 out of 66 family members (30.3%) car-
ried the T377M mutation. Two out of 14 Epirus POAG 
cases (14.2%) with positive family history had the T377M 
Figure 1 examples of the results obtained from the molecular analysis. Lanes 1 and 5: PhiX174 DnA/hinfi marker; Lanes 2 and 8: blank; Lanes 3 and 4: heterozygotes for 
the T377M mutation (740 bp, 443 bp, 297 bp, and 80 bp bands are visible); Lanes 6 and 7: normal DnA samples not harboring the T377M mutation (740 bp, and 80 bp bands 
are visible). The 54 bp band was not visible in the gel.Clinical Ophthalmology 2010:4 174
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mutation, whereas only one out of 80 sporadic Epirus POAG 
cases (1.2%) carried this mutation (exact P = 0.057 for the 
comparison of familial versus sporadic POAG cases). Fur-
thermore, the T377M mutation was not detected among 124 
Epirus inhabitants without POAG (controls) (exact P  0.001 
for the comparison against POAG cases). Moreover, none of 
the four sporadic POAG cases from the Chrysovitsa village 
(not belonging to the large family described above) had the 
T377M mutation.
Clinical features for T377M carriers  
with POAg
The clinical findings in carriers of the T377M mutation from 
Epirus are presented in Table 2. Of these, 15 had a diagnosis 
of POAG (12 from the Chrysovitsa family, 2 other familial 
cases, 1 sporadic case). Eight cases of POAG had severe visual 
defects and 7 had modest visual defects. In Kaplan-Meier 
analysis, the probability of POAG diagnosis with advancing 
age among mutation carriers was 23% at age 40, and reached 
100% at age 75. Three individuals had undergone surgery in 
both eyes (trabeculectomy) and one (F3-38) definitely needed 
surgical therapy but was unwilling to comply. Also, in T377M 
mutation carriers, the probability of developing glaucoma 
with advancing age in GLC1C and non-GLC1C individuals 
is shown in a Kaplan–Meier plot in Figure 2.
Clinical features in POAg: T377M 
carriers versus non-carriers
The mean age at diagnosis ± SD, mean age at examination ± 
SD, mean maximum IOP ± SD, and mean maximum cup/
disc ratio ± SD in the various groups of Epirus individuals 
are presented in Table 3. POAG patients with the T377M 
mutation were diagnosed at 51 ± 13.9 years of age, which is 
younger than the sporadic or familial POAG cases without 
T377M: 63.1 ± 11 and 66.8 ± 9.8 years of age, respectively 
(P  0.001 for POAG cases with versus without T377M). 
The mean maximum IOP (31.9 ± 8.5 mm Hg) was not much 
higher in the T377M POAG group than in the sporadic or 
familial POAG groups without T377M (28.1 ± 7.1 mm Hg 
and 29.1 ± 6.3 mm Hg, respectively). Finally, there were no 
significant differences in the cup/disc ratio for T377M car-
riers versus non-carriers with POAG (Table 3).
Discussion
We have examined the prevalence of the T377M MYOC muta-
tion in diverse groups of patients with POAG and unaffected 
controls in the region of Epirus in Northwestern Greece. 
Our findings suggest that T377M is largely concentrated 
in the originally described family from Chrysovitsa, where 
almost one in four members (15/66) are affected by POAG.26 
However, some other familial glaucoma cases from the region 
also carry this mutation, while the mutation is very rare in 
sporadic POAG cases and virtually absent in unaffected con-
trols from the general Epirus population. POAG associated 
with T377M in this region is associated with early onset in 
a substantial proportion of cases and practically complete 
penetrance of the disease by age 75, but otherwise the severity 
of the illness is not much worse compared with cases without 
T377M from the same region.
Hereditary diseases are occasionally frequent in small 
populations that have been living in relative isolation for a 
long time. When a mutation was introduced by a founder in 
an isolated population, it could have a chance to become fre-
quent even in spite of selection against it. One such example 
of an isolated population is the Northwest region of Greece, 
Epirus. The Chrysovitsa village in the Pindus Mountains of 
the Epirus region of Greece has been isolated for centuries. 
Eleven pedigrees from Epirus segregating adult onset POAG 
in an autosomal dominant mode were described by Kitsos 
et al.30 Linkage analysis in the largest of these pedigrees, habi-
tating the small village of Chrysovitsa (population of 993 in 
2001) on Mount Pindus, showed linkage to the GLC1C locus 
Table 1 Frequency of the T377M MYOC mutation in different categories of examined individuals from epirus, greece
Groups Number of individuals Number of T377M carriers Proportion (95% CI)
sporadic POAg (epirus) 80a 1 1.2 (0.0–6.8)
Familial POAg (epirus) 14b 2 14.2 (1.8–42.8)
Chrysovitsa family 66c 20d 30.3 (19.6–42.9)
epirus controls 124e 0 0.0 (0.0–2.9)
sporadic POAg (Chrysovitsa) 4 0 0.0 (0.0–60.2)
Chrysovitsa controls 4 0 0.0 (0.0–60.2)
anumber includes four cases from the Chrysovitsa village; bFrom unrelated families; cFifteen family members had been diagnosed with POAg; dTwelve T377M carriers had 
POAg; enumber includes 4 individuals from the Chrysovitsa village.
Abbreviation: POAg, primary open-angle glaucoma.Clinical Ophthalmology 2010:4 175
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at 3q21-q24,26 which had originally been described in a large 
family from Oregon, USA.31 Due to the usually multifacto-
rial mode of inheritance of adult onset POAG, both GLC1C 
families were screened for mutations in the MYOC gene.24 
Interestingly, the T377M mutation was found in 67% (10/15) 
of the POAG patients of the Chrysovitsa family in an earlier 
evaluation of the same family.24 Taxiarchis, another small 
Greek village (∼1100 inhabitants) on Mount Holomondas 
in the Chalkidiki region, known to be enriched for familial 
glaucoma,32 was recently studied by Wirtz et al.33 The inci-
dence of glaucoma was 17% (22/126) and the T377M MYOC 
mutation was detected in 59% (13/22) of the POAG patients. 
The haplotype of the T377M mutation in Taxiarchis villagers 
was the same as in the Chrysovitsa villagers.33
As evident from Table 1, acknowledging that some of the 
data are sparse, the mutation seems to occur in a considerable 
proportion of familial POAG cases from Epirus, as compared 
to the low proportion found in the sporadic POAG cases 
from the same region. One of the T377M mutation carriers 
(K151 – Table 2), a 63-year-old lady of Vlach ancestry (both 
parents) with familial glaucoma, was born in Kefalovryso 
(father and her 2 sisters: POAG patients). The other familial 
case (K153 – Table 2), an 84-year-old man, was born in Per-
dika (4/5 brothers and his son: POAG patients). The T377M 
sporadic case (20DC – Table 2) originates from Kastritsa 
(both parents and all 5 brothers/sisters: healthy – no POAG). 
The above 3 small villages are located at a 60-70 km distance 
from Chrysovitsa (Figure 3). None of these individuals has 
any known relation to Chrysovitsa going back 2 generations 
(origin of grandparents). The Taxiarchis village is located 
about 300 km from Chrysovitsa and there is oral information 
from Taxiarchis villagers that a route existed between the 
two villages, which was traveled frequently, at times to bring 
young women from Chrysovitsa to Taxiarchis for marriage 
Table 2 Clinical findings in carriers of the T377M MYOC mutation from epirus, greece
IDa Year of POAG GLC1C Age at Age at Max Max cup/ Visual Surgery
birth examination diagnosis intraocular disc ratio fields (trabeculectomy)
            pressure      
F2-3 1909 Yes Yes 85 75 28 0.9 sD no
F2-5 1917 Yes Yes 84 67 56 0.95 sD no
F2-6 1924 Yes Yes 77 60 23 0.8 sD no
F2-7 1927 Yes Yes 74 57 26 0.4 MD no
F2-8 1930 Yes Yes 71 54 43 0.9 sD no
F3-6 1949 Yes 55 36 30 0.6 MD no
F3-11 1940 no 69 18 0.3 no
F3-14 1949 no 60 19 0.2 no
F3-19 1951 no 58 20 0.2 no
F3-22 1948 no Yes 61 19 0.3 no
F3-25 1957 Yes 44 34 36 0.5 MD Yes OD/Os
F3-38 1960 Yes Yes 41 36 30 0.7 sD no
F3-27 1947 no 62 14 0.3 no
F3-29 1955 Yes Yes 54 39 27 0.5 MD no
F3-37 1958 Yes 51 46 32 0.6 MD no
F3-31 1958 Yes 43 43 26 0.5 MD no
F3-32 1959 OhT 50 22 0.2 no
F3-34 1964 no Yes 45 20 0.4 no
F3-35 1970 Yes Yes 35 32 36 0.9 sD no
F4-27 1980 no 29 16 0.4 no
20DC 1928 Yes 80 70 27 0.8 sD Yes OD/Os
K151 1946 Yes 59 58 24 0.7 MD no
K153 1925 Yes 80 67 35 0.9 sD Yes OD/Os
aThe F individuals indicate members of the Chrysovitsa family, the 20DC individual is a sporadic POAg case, whereas the K individuals are familial POAg cases.
Abbreviations: sD, severe defect – advanced glaucomatous loss; MD, moderate defect – moderate glaucomatous loss; OhT, ocular hypertension; POAg, primary open-angle 
glaucoma; OD, right eye; Os, left eye.Clinical Ophthalmology 2010:4 176
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to local men in order to bring “new blood” into the village. 
In the study by Hewitt et al,16 six pedigrees shared the same 
“Greek” haplotype: the Chrysovitsa family, 2 Australian 
families, 2 USA families of Greek origin, and 1 family from 
FYROM, which is in close geographic proximity to Epirus. 
Furthermore, we had oral information from the examined 
patients that the two Australian families as well as one from 
the two US families originated from the Epirus region. In 
another recent paper from Croatia,25 a small isolated village 
called Veli Brgud in the mountains of the Istrian peninsula 
(population 550), with a previously reported high prevalence 
of early onset POAG, was investigated. Nine out of 16 POAG 
patients that were examined, carried the T377M MYOC 
mutation. There has been no haplotype analysis so far to 
link the above cases to the known “Greek” haplotype, but 
the distance from this village to the Epirus Region is about 
800 km in straight line. It is conceivable that all these cases 
in southeastern Europe may point to a common founder, with 
family members migrating to different places of the region 
over the last several centuries.
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Figure 2 T377M carriers: Probability of developing glaucoma with advancing age for GLC1C and non-GLC1C individuals (Kaplan–Meier plot).
Table 3 Comparison of clinical features in T377M MYOC carriers with POAg versus other groups of individuals from epirus, greece
Groups Mean (±SD) age at 
diagnosis (years)
Mean (±SD) age at 
examination (years)a
Mean (±SD) max IOP 
(mmHg)a
Mean (±SD) max 
cup/disc ratioa
T377M carriers with POAg 
(n = 15)
51.0 (13.9) 61.5 (17.5) 31.9 (8.5) 0.67 (0.2)
sporadic POAg without 
T377M (n = 79)
63.1 (11.0) 70.0 (10.0) 28.1 (7.1) 0.60 (0.21)
Chrysovitsa POAg and OhT 
without T377M (n = 12)a
48.0 (16.9) 51.7 (17.3) 24.9 (4.2) 0.49 (0.28)
Familial POAg without 
T377M (n = 12)
66.8 (9.8) 76.4 (12.9) 29.1 (6.3) 0.69 (0.18)
Controls (n = 124) – 74.2 (8.4) 14.6 (2.2) 0.25 (0.1)
aFour individuals were sporadic POAg cases and 8 were from the Chrysovitsa GLC1C family (3 with POAg and 5 with OhT).
Abbreviations: OhT, ocular hypertension; POAg, primary open-angle glaucoma.Clinical Ophthalmology 2010:4 177
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In summary, 2 isolated small Greek villages, known 
to be enriched for glaucoma, Chrysovitsa from our study 
and 1 at 300 km distant from it, were shown to harbor the 
T377M MYOC mutation on the same haplotype, a Greek 
founder mutation probably originating from the Epirus 
region. Furthermore, in our study, the mutation was found 
in relatively high proportion in familial POAG cases but 
seems rare among sporadic cases from the same region, 
while there was no mutation carrier found in the control 
group.
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